30 closest matches · ranked by relevance
Superficial Thrombophlebitis · Upper Extremity Superficial Thrombophlebitis · Lower Extremity Superficial Thrombophlebitis
Primary: Thrombosis Progression and Venous Thromboembolism (VTE) — 4; 0; 0; 0 participants
Thrombosis, Venous
Primary: Number of Participants With at Least on Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 47 — 13; 88 participants — p=<0.001
Superficial Vein Thrombosis
Primary: Rate of Objectively Confirmed VTE Complications — 7; 4 Participants — p=0.0252
Deep-Vein Thrombosis
Primary: Percentage of Participants That Died at 3 Months — 8; 0 percentage of participants
Catheter Infection · Catheter Thrombosis · Catheter Complications
Primary: Upper Extremity CR-UEVT — 7; 11 Participants
Deep Vein Thrombosis · Venous Thrombosis · Postphlebitic Syndrome
Primary: Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) — 157; 171 Participants — p=0.56
Deep Vein Thrombosis · Post-thrombotic Syndrome
Primary: Change From Baseline in Villalta Score at Day 30 Post-EkoSonic® Study Treatment Procedure — 15.5; -5.9 units on a scale
Venous Leg Ulcer
Primary: Change From Baseline in Wound Perimeter — 29.36; 43.64 mm
Deep Vein Thrombosis
Primary: To Provide Estimates of the Specificity of [99mTc] ThromboView® in Patients With Excluded Initial DVT — 76.9; 65.4; 100; 96.2 % Specificity
Femoral Artery Stenosis · Popliteal Artery Stenosis · Femoral Artery Occlusion
Primary: Number and Percentage of Participants With Freedom of Major Adverse Event (MAE) Rate — 72 Participants
Deep Venous Thrombosis
Primary: Incidence of Post-thrombotic Syndrome (PTS) — 44; 37 participants — p=.58
Chronic Venous Insufficiency
Primary: Mean Change (Reduction) From Baseline in Volume of Reference Leg at Week 16 — 1.13; 5.78 milliliters (mL) — p=0.531
Venous Thrombosis · Neoplasms
Primary: PTS Assessment Completion — 17 Participants
Venous Thromboses · Venous Thromboembolism · Deep Vein Thrombosis
Primary: Risk of Venous Thromboembolism (VTE) — 335; 845; 132; 3804 Participants
Venous Thromboembolism · Atopic Dermatitis · Pulmonary Embolism
Primary: Number of Participants With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person. — 2576; 7563 Participants
Venous Thromboembolism · Venous Thrombosis
Primary: Number of Patients With Asymptomatic Venous Thrombosis of Lower Limbs as Detected by Duplex Ultrasound — 1; 34 Participants — p=<0.001
Acute Deep Vein Thrombosis
Primary: 2-year Change in Villalta Score — -1.5; -0.5 units on a scale — p=0.34
Varicose Veins
Primary: Change in Patient-reported Symptoms of Varicose Veins (VVSymQ Score) — 2.13; 4.63; 5.68; 4.87 units on a scale — p==0.0001
Varicose Veins
Primary: Change in Patient-Reported Symptoms of Varicose Veins (VVSymQ Score) — -2.00; -5.34; -6.01; -5.06 units on a scale — p=<0.0001
Acute Deep Venous Thrombosis of the Lower Extremity
Primary: Number of Participants With Restored Venous Function — 28 participants
Liver Cirrhosis · Portal Vein Thrombosis
Primary: Recanalization Rate — 20; 11 Participants
Venous Stasis Ulcers
Primary: Safety and Tolerability of Thymosin Beta 4 (Tβ4) Applied to Patients With Venous Stasis (VS) Ulcers for up to 84 Days — 24; 104 SAEs and AEs
Venous Thrombosis
Primary: Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment — 0.0226; 0.0269 proportion…
Great Saphenous Vein Incompetence · Visible Varicosities
Primary: Absolute Change From Baseline in Independent Photography Review (IPR-V3 Score) — -0.80; -1.30; -1.11 score
Thrombosis
Primary: Total Number of Participants Who Completed the Study-Related Ultrasound (US) and Magnetic Resonance Imaging (MRI) With and Without Contrast — 133; 113; 113; 110…
Peripheral Vascular Disease
Primary: Primary Safety Endpoint: Freedom From Death, Target Lesion Revascularization (TLR), or Any Amputation of the Index Limb to 30 (±7) Days. — 99.2; 99.6; 99.6; 100.0…
Venous Thrombosis
Primary: Evidence of PICC-related Venous Thrombosis — 102; 95 Participants
Atherosclerosis of Native Arteries of the Extremities
Primary: Primary Patency — 94.4 percentage of lesions
Spinal Surgery · Vascular Surgery
Primary: Number of Participants With Anti-recombinant Thrombin (rThrombin) Product Antibodies at Day 29 in Participants With and Without Anti-bovine Thrombin Product Antibodies…
Vascular Diseases · Embolism and Thrombosis · Phlebitis
Primary: Percentage of Participants Who Developed a New or Recurrence of Venous Thromboembolism (VTE) — 8.94 percentage of participants